Literature DB >> 15382957

Management of autoimmune skin disorders in the elderly.

Wei Jing Loo1, Nigel P Burrows.   

Abstract

Senescence of the skin immunological system may explain why the elderly population has an increased susceptibility to certain autoimmune skin disorders. These disorders are characterised by the production of either antibodies that react with host tissue or immune effector T cells that are autoreactive. Bullous pemphigoid is the most common autoimmune blistering disease in the elderly. Although oral corticosteroids are the best established therapy, high-potency topical corticosteroids are very useful as initial treatment and, in the elderly, should be used instead of oral prednisolone wherever possible. Pemphigus is a chronic blistering disease of which there are two main subtypes: vulgaris and foliaceous. Paraneoplastic pemphigus is a unique clinical, histological and immunologically distinct autoimmune mucocutaneous disease which tends to be relentlessly progressive. Lichen sclerosus presents specific complications and a small but definite increased risk of squamous cell carcinoma in elderly patients. It is important to be aware of practical issues such as the difficulty in applying topical corticosteroids, the mainstay treatment of this condition. Dermatomyositis is an autoimmune systemic disorder where the skin and muscles are the most commonly affected organs. Tumour-associated disease occurs more commonly in elderly patients and has a poorer prognosis. Management of the disease includes sunscreens, topical or systemic corticosteroids, antimalarials, oral immunosuppressants or intravenous immunoglobulins. It is important to bear in mind that old age modifies the management of skin diseases because of physical and social circumstances as well as the unwanted adverse effects of medications. Polypharmacy results in an increased risk of drug interactions and, therefore, drug regimens need to be kept as simple as possible. Drug-induced autoimmune skin eruptions are common amongst the elderly and usually resolve when the offending drug is discontinued.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15382957     DOI: 10.2165/00002512-200421120-00002

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  43 in total

1.  High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases.

Authors:  K E Harman; M M Black
Journal:  Br J Dermatol       Date:  1999-05       Impact factor: 9.302

2.  Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid.

Authors:  J C Guillaume; L Vaillant; P Bernard; C Picard; C Prost; B Labeille; B Guillot; C Foldès-Pauwels; F Prigent; P Joly
Journal:  Arch Dermatol       Date:  1993-01

3.  The correlation of disease activity and antibody titers in pemphigus.

Authors:  R E Fitzpatrick; V D Newcomer
Journal:  Arch Dermatol       Date:  1980-03

Review 4.  Hydroxychloroquine neuromyotoxicity.

Authors:  M Stein; M J Bell; L C Ang
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

5.  A clinical study of 23 cases of female anogenital carcinoma.

Authors:  E K Derrick; C M Ridley; A Kobza-Black; P H McKee; S M Neill
Journal:  Br J Dermatol       Date:  2000-12       Impact factor: 9.302

6.  [Cyclosporin in the treatment of bullous pemphigoid: preliminary study].

Authors:  H Barthélémy; J Thivolet; F Cambazard; A Bendelac; G Mauduit; F Granier; A Frappaz
Journal:  Ann Dermatol Venereol       Date:  1986       Impact factor: 0.777

7.  Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients.

Authors:  Agnès Sparsa; Eric Liozon; François Herrmann; Kim Ly; Valérie Lebrun; Pascale Soria; Véronique Loustaud-Ratti; Marie-Laure Bouyssou-Gauthier; Serge Boulinguez; Christophe Bédane; Marie-Odile Jauberteau; Elisabeth Vidal; Jean-Marie Bonnetblanc
Journal:  Arch Dermatol       Date:  2002-07

8.  Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up.

Authors:  W Aberer; E C Wolff-Schreiner; G Stingl; K Wolff
Journal:  J Am Acad Dermatol       Date:  1987-03       Impact factor: 11.527

9.  Mycophenolate is effective in the treatment of pemphigus vulgaris.

Authors:  A H Enk; J Knop
Journal:  Arch Dermatol       Date:  1999-01

10.  Treatment of bullous pemphigoid with topical clobetasol propionate.

Authors:  W Westerhof
Journal:  J Am Acad Dermatol       Date:  1989-03       Impact factor: 11.527

View more
  3 in total

Review 1.  Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management.

Authors:  Minhee Kim; Luca Borradori; Dédée F Murrell
Journal:  Drugs Aging       Date:  2016-10       Impact factor: 3.923

2.  Alopecia Areata in the Elderly: A 10-Year Retrospective Study.

Authors:  Yong Hyun Jang; Kyung Hea Park; Sang Lim Kim; Hyun Jung Lim; Weon Ju Lee; Seok-Jong Lee; Do Won Kim
Journal:  Ann Dermatol       Date:  2015-07-29       Impact factor: 1.444

3.  Skin diseases among elderly inhabitants of Bialystok, Poland.

Authors:  Mateusz Cybulski; Elzbieta Krajewska-Kulak
Journal:  Clin Interv Aging       Date:  2015-12-08       Impact factor: 4.458

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.